HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress

Journal of Lipid Research

Volumn 49, Issue 6, 2008, Pages 1246-1253

  Moren, Xenia ^a   Deakin, Sara ^a   Liu, Ming Lin ^b   Taskinen, Marja Riitta ^c   James, Richard W ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

ApoA I; ApoA II; Atherosclerosis; Lipoprotein

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; RECOMBINANT ENZYME; ARYLDIALKYLPHOSPHATASE;

ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME STABILITY; FEMALE; HUMAN; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; ANIMAL; BLOOD; CHO CELL; CRICETULUS; HAMSTER; LIQUID CHROMATOGRAPHY; METABOLISM;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CHO CELLS; CHROMATOGRAPHY, LIQUID; CRICETINAE; CRICETULUS; ENZYME STABILITY; LIPOPROTEINS, HDL; OXIDATIVE STRESS;

EID: 48549098997     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700439-JLR200     Document Type: Article

References (33)

1. Kontush, A., and M. J. Chapman. 2006. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58: 342-374.
2. Cheung, M. C., and J. J. Albers. 1984. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: particles containing A-I and A-II and particles containing A-I but no A-II. J. Biol. Chem. 259: 12201-12209.
3. James, R. W., and D. Pometta. 1990. Immunfractionation of high-density lipoprotein subclasses 2 and 3: similarities and differences of fractions isolated from male and female populations. Atherosclerosis. 83: 35-45.
4. Kalopissis, A. D., D. Pastier, and J. Chambaz. 2003. Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance. Curr. Opin. Lipidol. 14: 165-172.
5. Tailleux, A., P. Duriez, J. C. Fruchart, and V. Clavey. 2002. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis. 164: 1-13. (Pubitemid 34765632)
6. Warden, C. H., C. C. Hedrick, J. H. Qiao, L. W. Castellani, and A. J. Lusis. 1993. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 261: 469-472. (Pubitemid 23276555)
7. Castellani, L. W., M. Navab, B. J. Van Lenten, C. C. Hendrick, S. Y. Hama, A. M. Goto, A. M. Fogelman, and A. J. Lusis. 1997. Overexpression of apolipoprotein A-II in transgenic mice converts high density lipoproteins to pro-inflammatory particles. J. Clin. Invest. 100: 464-474.
8. Boucher, J., T. A. Ramsamy, S. Braschi, D. Sahoo, T. A. Neville, and D. L. Sparks. 2004. Apolipoprotein A-II regulates HDL stability and affects hepatic lipase association and activity. J. Lipid Res. 45: 849-858. (Pubitemid 38552854)
9. James, R. W., and S. P. Deakin. 2004. The importance of highdensity lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic. Biol. Med. 37: 1986-1994.
10. La Du, B. N. 1992. Human serumparaoxonase/arylesterase. In Pharmacogenetics of Drug Metabolism. W. Kalow, editor. Pergamon Press, New York. 51-91.
11. Blatter, M-C., R. W. James, S. Messmer, F. Barja, and D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
12. Deakin, S., I. Leviev, M. Gomaraschi, L. Calabresi, G. Franceschini, and R. W. James. 2002. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 277: 4301-4308.
13. Graner, M., R. W. James, J. Kahri, M. S. Nieminen, M. Syvanne, and M. R. Taskinen. 2006. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J. Am. Coll. Cardiol. 47: 2429-2435.
14. James, R. W., D. Hochstrasser, J-D. Tissot, M. Funk, R. Appel, F. Barja, C. Pellegrini, A. F. Muller, and D. Pometta. 1988. Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II, isolated from human plasma. J. Lipid Res. 29: 1557-1571. (Pubitemid 19030524)
15. Blatter Garin, M-C., C. Abbot, S. Messmer, M. I. Mackness, P. Durrington, D. Pometta, and R. W. James. 1994. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem. J. 304: 549-554. (Pubitemid 24368237)
16. Lamarche, B., K. D. Uffelman, A. Carpentier, J. S. Cohn, G. Steiner, P. H. Barrett, and G. F. Lewis. 1999. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J. Clin. Invest. 103: 1191-1199.
17. Havel, R. J., H. A. Eder, and J. H. Bragton. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
18. Aharoni, A., L. Gaidukov, S. Yagur, L. Toker, I. Silman, and D. S. Tawfik. 2004. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. USA. 101: 482-487.
19. Deakin, S., X. Moren, and R. W. James. 2007. HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler. Thromb. Vasc. Biol. 27: 1146-1152.
20. Jonas, A. 1986. Reconstitution of high density lipoproteins. Methods Enzymol. 128: 553-581.
21. Hime, N. J., K. J. Drew, K. Wee, P. J. Barter, and K. A. Rye. 2006. Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit. J. Lipid Res. 47: 115-122. (Pubitemid 43107455)
22. Leviev, I., and R. W. James. 2000. Promoter polymorphisms of the human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20: 516-521.
23. Liu, M-L., R. W. James, K. Ylitalo, and M-R. Taskinen. 2004. Associations between HDL oxidation and paraoxonase-1 gene polymorphisms in familial combined hyperlipidemic family members. Nutr. Metab. Cardiovasc. Dis. 14: 81-87.
24. Deakin, S., X. Moren, and R. W. James. 2005. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis. 179: 17-25. (Pubitemid 40249782)
25. Gaidukov, L., and D. S. Tawfik. 2005. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry. 44: 11843-11854. (Pubitemid 41262719)
26. Oda, M. N., J. K. Bielicki, T. Berger, and T. M. Forte. 2001. Cysteine substitutions in apolipoprotein A-I primary structure modulate paraoxonase activity. Biochemistry. 40: 1710-1718. (Pubitemid 32144041)
27. Sorenson, R. C., C. L. Bisgaier, M. Aviram, C. Hsu, S. Billecke, and B. N. La Du. 1999. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19: 2214-2225.
28. Ribas, V., J. L. Sanchez-Quesada, R. Anton, M. Camacho, J. Julve, J. C. Escola-Gil, L. Vila, J. Ordonez-Llanos, and F. Blanco-Vaca. 2004. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ. Res. 95: 789-797.
29. Boisfer, E., D. Stengel, D. Pastier, P. M. Laplaud, N. Dousset, E. Ninio, and A. D. Kalopissis. 2002. Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. J. Lipid Res. 43: 732-741. (Pubitemid 34477900)
30. Bielicki, J. K., and M. N. Oda. 2002. ApoA-IMilano and apoA-IParis exhibit an antioxidant activity distinct from that of wild-type apoA-I. Biochemistry. 41: 2089-2096.
31. Blanco-Vaca, F., D. P. Via, C. Y. Yang, J. B. Massey, and H. J. Pownall. 1992. Characterization of disulfide-linked heterodimers containing apolipoprotein D in human plasma lipoproteins. J. Lipid Res. 33: 1785-1796. (Pubitemid 23006655)
32. James, R. W., and D. Pometta. 1994. Postprandial lipemia differentially influences high density lipoprotein subpopulations LpA-I and LpA-I,A-II. J. Lipid Res. 35: 1583-1591. (Pubitemid 24291219)
33. Patsch, J. R., A. M. J. Gotto, T. Olivercrona, and S. Eisenberg. 1978. Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro. Proc. Natl. Acad. Sci. USA. 75: 4519-4523.